"The pharmacological and pharmacokinetic profile of the prescribed antidepressant is a reliable predictor of ADS risk. For most, ADS symptoms are more common after the sudden discontinuation of antidepressants (Baldwin et al., 2007), especially SRIs, for example paroxetine and sertraline (Thompson, 1998), and SNRIs, for example venlafaxine (Agelink et al., 1997) and duloxetine (Warner et al., 2006), but also atypical agents such as mirtazapine (Berigan, 2001) and trazodone (Peabody, 1987). Clinical experience strongly suggests that a short T½ provides added risk (e.g. "
"Various withdrawal symptoms have been repeatedly described for all subclasses of antidepressants and include mainly mild changes in mood, vegetative functions and sleep (Lejoyeux and Ades, 1997). Venlafaxine, as a potent serotonine and noradrenaline reuptake inhibitor with a relatively short half-life of about 5 h (11 h for its main metabolite O-desmethyl-venlafaxine) seems to cause a particularly strong REM sleep suppression (Salin- Pascual et al., 1997) and may be especially potent to induce withdrawal reactions including a marked REM rebound after discontinuation (Agelnik et al., 1997). The high REM sleep pressure may result in SOREMPs during sleep and even multiple cataplectic attacks during waking caused by short REM sleep episodes with the REM typical inhibition of alphamotoneurons and muscle atonia. "
[Show abstract][Hide abstract] ABSTRACT: Introduction
Venlafaxine is an antidepressant that selectively inhibits serotonin reuptake and is a norepinephrine inhibitor. Withdrawal syndromes can occur after abrupt drug discontinuation of long-term regimens.
We report six cases of withdrawal symptoms after venlafaxine discontinuation.
Physicians must be aware of the frequency, rapidity and potent severity of these withdrawal syndromes.
La Revue de Médecine Interne 03/2000; 21(3):282-284. DOI:10.1016/S0248-8663(00)80048-X · 1.07 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.